Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Mar 10;100(7):1111–1119. doi: 10.1038/sj.bjc.6604965

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2009 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Vascular endothelial growth factor and RCC supernatants added to DC differentiation cultures inhibit maturation-induced surface markers on DC: effects of bevacizumab, sorafenib and sunitinib. Dendritic cells obtained from monocytes in 7-day cultures with GM-CSF and IL-4 were analysed by surface immunostaining and flow cytometry for the indicated leukocyte differentiation antigens before and after maturation in the presence of TNF-α, IFN-α and poly I:C. As indicated, recombinant VEGF (A) or RCC supernatants (B) were added during differentiation. When indicated, bevacizumab, sorafenib or sunitinib was also added during the differentiation cultures. Values are expressed as mean±s.e.m. of four different experiments. ^**P<0.01,^***P<0.001, statistical analyses were performed by the Kruskal–Wallis statistical test. In all cultures set up with CD14⁺ cells, the expression of CD14 was lost, so at the end of the cultures <1% cells were CD14⁺.